vs
Certara, Inc.（CERT）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Certara, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.4倍（$103.6M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 3.3%），Certara, Inc.自由现金流更多（$27.8M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 3.6%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CERT vs PBYI — 直观对比
营收规模更大
CERT
是对方的1.4倍
$75.5M
营收增速更快
PBYI
高出24.4%
3.3%
自由现金流更多
CERT
多$13.4M
$14.4M
两年增速更快
PBYI
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $103.6M | $75.5M |
| 净利润 | $-5.9M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 0.8% | 22.7% |
| 净利率 | -5.7% | — |
| 营收同比 | 3.3% | 27.7% |
| 净利润同比 | -189.6% | — |
| 每股收益（稀释后） | $-0.04 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTPBYI
| Q4 25 | $103.6M | $75.5M | ||
| Q3 25 | $104.6M | $54.5M | ||
| Q2 25 | $104.6M | $52.4M | ||
| Q1 25 | $106.0M | $46.0M | ||
| Q4 24 | $100.4M | $59.1M | ||
| Q3 24 | $94.8M | $80.5M | ||
| Q2 24 | $93.3M | $47.1M | ||
| Q1 24 | $96.7M | $43.8M |
净利润CERTPBYI
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $1.5M | $8.8M | ||
| Q2 25 | $-2.0M | $5.9M | ||
| Q1 25 | $4.7M | $3.0M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $-1.4M | $20.3M | ||
| Q2 24 | $-12.6M | $-4.5M | ||
| Q1 24 | $-4.7M | $-4.8M |
毛利率CERTPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CERTPBYI
| Q4 25 | 0.8% | 22.7% | ||
| Q3 25 | 2.9% | 17.6% | ||
| Q2 25 | 9.1% | 12.7% | ||
| Q1 25 | 7.2% | 8.7% | ||
| Q4 24 | 6.0% | 22.6% | ||
| Q3 24 | 2.7% | 27.4% | ||
| Q2 24 | -9.7% | -4.6% | ||
| Q1 24 | -1.3% | -5.3% |
净利率CERTPBYI
| Q4 25 | -5.7% | — | ||
| Q3 25 | 1.5% | 16.2% | ||
| Q2 25 | -1.9% | 11.2% | ||
| Q1 25 | 4.5% | 6.5% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | -1.4% | 25.2% | ||
| Q2 24 | -13.5% | -9.6% | ||
| Q1 24 | -4.8% | -11.0% |
每股收益（稀释后）CERTPBYI
| Q4 25 | $-0.04 | $0.26 | ||
| Q3 25 | $0.01 | $0.17 | ||
| Q2 25 | $-0.01 | $0.12 | ||
| Q1 25 | $0.03 | $0.06 | ||
| Q4 24 | $0.04 | $0.40 | ||
| Q3 24 | $-0.01 | $0.41 | ||
| Q2 24 | $-0.08 | $-0.09 | ||
| Q1 24 | $-0.03 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.4M | $97.5M |
| 总债务越低越好 | $293.1M | $22.7M |
| 股东权益账面价值 | $1.1B | $130.3M |
| 总资产 | $1.6B | $216.3M |
| 负债/权益比越低杠杆越低 | 0.28× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CERTPBYI
| Q4 25 | $189.4M | $97.5M | ||
| Q3 25 | $172.7M | $94.4M | ||
| Q2 25 | $162.3M | $96.0M | ||
| Q1 25 | $179.1M | $93.2M | ||
| Q4 24 | $179.2M | $101.0M | ||
| Q3 24 | $233.0M | $96.7M | ||
| Q2 24 | $224.6M | $96.8M | ||
| Q1 24 | $224.8M | $107.2M |
总债务CERTPBYI
| Q4 25 | $293.1M | $22.7M | ||
| Q3 25 | $293.5M | $34.0M | ||
| Q2 25 | $294.2M | $45.3M | ||
| Q1 25 | $294.8M | $56.7M | ||
| Q4 24 | $295.4M | $68.0M | ||
| Q3 24 | $296.1M | $79.3M | ||
| Q2 24 | $296.7M | $90.7M | ||
| Q1 24 | $290.8M | $102.0M |
股东权益CERTPBYI
| Q4 25 | $1.1B | $130.3M | ||
| Q3 25 | $1.1B | $115.3M | ||
| Q2 25 | $1.1B | $104.7M | ||
| Q1 25 | $1.1B | $97.1M | ||
| Q4 24 | $1.1B | $92.1M | ||
| Q3 24 | $1.1B | $71.1M | ||
| Q2 24 | $1.0B | $48.5M | ||
| Q1 24 | $1.1B | $51.0M |
总资产CERTPBYI
| Q4 25 | $1.6B | $216.3M | ||
| Q3 25 | $1.5B | $202.9M | ||
| Q2 25 | $1.5B | $194.9M | ||
| Q1 25 | $1.6B | $196.2M | ||
| Q4 24 | $1.6B | $213.3M | ||
| Q3 24 | $1.5B | $220.7M | ||
| Q2 24 | $1.5B | $205.0M | ||
| Q1 24 | $1.5B | $214.1M |
负债/权益比CERTPBYI
| Q4 25 | 0.28× | 0.17× | ||
| Q3 25 | 0.28× | 0.30× | ||
| Q2 25 | 0.27× | 0.43× | ||
| Q1 25 | 0.27× | 0.58× | ||
| Q4 24 | 0.28× | 0.74× | ||
| Q3 24 | 0.28× | 1.12× | ||
| Q2 24 | 0.28× | 1.87× | ||
| Q1 24 | 0.28× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.8M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $27.8M | $14.4M |
| 自由现金流率自由现金流/营收 | 26.8% | 19.1% |
| 资本支出强度资本支出/营收 | 1.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $94.4M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CERTPBYI
| Q4 25 | $28.8M | $14.4M | ||
| Q3 25 | $32.3M | $9.7M | ||
| Q2 25 | $17.8M | $14.1M | ||
| Q1 25 | $17.4M | $3.6M | ||
| Q4 24 | $49.4M | $15.6M | ||
| Q3 24 | $17.0M | $11.0M | ||
| Q2 24 | $9.8M | $1.0M | ||
| Q1 24 | $4.3M | $11.2M |
自由现金流CERTPBYI
| Q4 25 | $27.8M | $14.4M | ||
| Q3 25 | $32.1M | $9.7M | ||
| Q2 25 | $17.8M | $14.1M | ||
| Q1 25 | $16.8M | $3.6M | ||
| Q4 24 | $49.0M | $15.6M | ||
| Q3 24 | $16.8M | $11.0M | ||
| Q2 24 | $9.4M | $1.0M | ||
| Q1 24 | $3.7M | — |
自由现金流率CERTPBYI
| Q4 25 | 26.8% | 19.1% | ||
| Q3 25 | 30.7% | 17.7% | ||
| Q2 25 | 17.0% | 26.8% | ||
| Q1 25 | 15.8% | 7.7% | ||
| Q4 24 | 48.8% | 26.4% | ||
| Q3 24 | 17.7% | 13.7% | ||
| Q2 24 | 10.1% | 2.1% | ||
| Q1 24 | 3.8% | — |
资本支出强度CERTPBYI
| Q4 25 | 1.0% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.6% | 0.1% | ||
| Q4 24 | 0.4% | 0.0% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.5% | 0.0% | ||
| Q1 24 | 0.6% | 0.0% |
现金转化率CERTPBYI
| Q4 25 | — | — | ||
| Q3 25 | 21.19× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 3.66× | 1.21× | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
